--- title: "A Peek at Exelixis's Future Earnings" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275346470.md" description: "Exelixis (NASDAQ:EXEL) is set to release its quarterly earnings report on February 10, 2026, with analysts expecting an EPS of $0.76. The company has shown positive performance, beating EPS estimates in the last quarter, leading to a 6.52% share price increase. Currently trading at $43.9, Exelixis has seen a 33.59% rise over the past year. Analysts rate the stock as a Buy, with a one-year price target of $49.5, indicating a potential upside. Exelixis excels in revenue growth and net margin compared to peers, showcasing strong financial health." datetime: "2026-02-09T17:01:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275346470.md) - [en](https://longbridge.com/en/news/275346470.md) - [zh-HK](https://longbridge.com/zh-HK/news/275346470.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275346470.md) | [English](https://longbridge.com/en/news/275346470.md) # A Peek at Exelixis's Future Earnings Exelixis (NASDAQ:EXEL) will release its quarterly earnings report on Tuesday, 2026-02-10. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Exelixis to report an **earnings per share** (EPS) of $0.76. The market awaits Exelixis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to understand that guidance can be a significant driver of stock prices. ### Earnings History Snapshot The company's EPS beat by $0.15 in the last quarter, leading to a 6.52% increase in the share price on the following day. Here's a look at Exelixis's past performance and the resulting price change: **Quarter** **Q3 2025** **Q2 2025** **Q1 2025** **Q4 2024** **EPS Estimate** 0.63 0.61 0.44 0.49 **EPS Actual** 0.78 0.75 0.62 0.55 **Price Change %** 7.00 \-17.00 21.00 0.00 ![eps graph](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ### Exelixis Share Price Analysis Shares of Exelixis were trading at $43.9 as of February 06. Over the last 52-week period, shares are up 33.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. ### Analysts' Perspectives on Exelixis Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Exelixis. The consensus rating for Exelixis is Buy, based on 6 analyst ratings. With an average one-year price target of $49.5, there's a potential 12.76% upside. ### Peer Ratings Comparison The following analysis focuses on the analyst ratings and average 1-year price targets of and BioMarin Pharmaceutical, three prominent industry players, providing insights into their relative performance expectations and market positioning. - Analysts currently favor an Buy trajectory for BioMarin Pharmaceutical, with an average 1-year price target of $80.4, suggesting a potential 83.14% upside. ### Peer Metrics Summary Within the peer analysis summary, vital metrics for and BioMarin Pharmaceutical are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance. Company Consensus Revenue Growth Gross Profit Return on Equity Exelixis Buy 10.79% $579.18M 9.23% BioMarin Pharmaceutical Buy 4.08% $636.05M \-0.51% Key Takeaway: Exelixis ranks higher than its peers in terms of revenue growth and gross profit. However, it has a lower return on equity compared to its peers. ### All You Need to Know About Exelixis Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. ### Financial Insights: Exelixis **Market Capitalization:** With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers. **Revenue Growth:** Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately **10.79%**. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. **Net Margin:** Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of **32.38%,** the company showcases strong profitability and effective cost management. **Return on Equity (ROE):** Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of **9.23%,** the company showcases efficient use of equity capital and strong financial health. **Return on Assets (ROA):** Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive **7.04%** ROA, the company effectively utilizes its assets for optimal returns. **Debt Management:** Exelixis's debt-to-equity ratio is below the industry average. With a ratio of **0.08**, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. To track all earnings releases for Exelixis visit their earnings calendar on our site. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### 相關股票 - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Exelixis (EXEL.US)](https://longbridge.com/zh-HK/quote/EXEL.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) ## 相關資訊與研究 - [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/zh-HK/news/281174211.md) - [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/zh-HK/news/281240360.md) - [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/zh-HK/news/281522861.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md) - [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/zh-HK/news/281174396.md)